Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2024 09:00 ET | Source: INVO Bioscience

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility,...
October 14, 2024 09:18 ET | Source: INVO Bioscience

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing...
August 14, 2024 09:00 ET | Source: INVO Bioscience

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced...
May 15, 2024 16:15 ET | Source: INVO Bioscience

INVO Reports Record First Quarter 2024 Financial Results

SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced...
April 16, 2024 16:59 ET | Source: INVO Bioscience

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced...
January 23, 2024 08:00 ET | Source: NAYA Biosciences

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed by Florida Biotechnologies, Inc. & the...
January 17, 2024 08:00 ET | Source: NAYA Biosciences

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...